(Q37063352)

18 August 2017

Imaging of the dopaminergic system in differential diagnosis of dementia (English)

1 reference

18 August 2017

0 references

0 references

1 reference

1

Klaus Tatsch

1 reference

PubMed ID

18214473

18 August 2017

language of work or name

1 reference

1 March 2008

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

18 August 2017

1 reference

18 August 2017

35 Suppl 1

1 reference

18 August 2017

S51-7

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-007-0702-0

18 August 2017

0 references

cites work

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1007%2FS00259-007-0702-0

Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-007-0702-0

Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-007-0702-0

PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-007-0702-0

1H MR spectroscopy in common dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-007-0702-0

Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

21 January 2018

1 reference

12 December 2020

Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.

1 reference

12 December 2020

Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease

1 reference

12 December 2020

European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.

1 reference

12 December 2020

PET studies in dementia

1 reference

12 December 2020

Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging

1 reference

12 December 2020

Imaging in dementia with Lewy bodies: a review

1 reference

12 December 2020

Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias

1 reference

12 December 2020

Imaging beta-amyloid burden in aging and dementia.

1 reference

12 December 2020

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

1 reference

12 December 2020

Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease.

1 reference

12 December 2020

Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease

1 reference

12 December 2020

Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.

1 reference

12 December 2020

Dementia with Lewy bodies

1 reference

12 December 2020

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

1 reference

12 December 2020

The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease.

1 reference

12 December 2020

Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients

1 reference

12 December 2020

In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies.

1 reference

12 December 2020

Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.

1 reference

12 December 2020

11C-DTBZ and 18F-FDG PET measures in differentiating dementias.

1 reference

12 December 2020

The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT).

1 reference

12 December 2020

Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease.

1 reference

12 December 2020

18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies

1 reference

12 December 2020

Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease

1 reference

12 December 2020

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

1 reference

12 December 2020

Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia

1 reference

12 December 2020

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

1 reference

12 December 2020

Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.

1 reference

12 December 2020

Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.

1 reference

12 December 2020

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

1 reference

12 December 2020

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

1 reference

12 December 2020

Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies.

1 reference

12 December 2020

10.1007/S00259-007-0702-0

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18214473